Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. - Wikidata - awgldk - TriplyDB

Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.

Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.

http://www.wikidata.org/entity/Q38363783

about

Cdc42-interacting protein 4 binds to huntingtin: neuropathologic and biological evidence for a role in Huntington's disease Mouse models of polyglutamine diseases: review and data table. Part I Maintenance of basal levels of autophagy in Huntington's disease mouse models displaying metabolic dysfunction Expression analysis of novel striatal-enriched genes in Huntington disease.Huntingtin-HAP40 complex is a novel Rab5 effector that regulates early endosome motility and is up-regulated in Huntington's disease.Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease.Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis Transcriptional activation of REST by Sp1 in Huntington's disease models cAMP-response element-binding protein and heat-shock protein 70 additively suppress polyglutamine-mediated toxicity in Drosophila Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175.Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation.Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.Transcription, epigenetics and ameliorative strategies in Huntington's Disease: a genome-wide perspective Components of the endocannabinoid and dopamine systems are dysregulated in Huntington's disease: analysis of publicly available microarray datasets.Experimental therapeutics in transgenic mouse models of Huntington's disease.Characterization of Behavioral, Neuropathological, Brain Metabolic and Key Molecular Changes in zQ175 Knock-In Mouse Model of Huntington's Disease Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease.Development of novel therapies for Huntington's disease: hope and challenge.Molecular diagnosis of neurogenetic disorders involving trinucleotide repeat expansions.Novel therapeutic targets for Huntington's disease.Microarrays in Parkinson's disease: a systematic approach.Transcriptional signatures in Huntington's disease.Drug targeting of dysregulated transcription in Huntington's disease Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for huntington disease.Molecular mechanisms and potential therapeutical targets in Huntington's disease.Huntington's disease: can mice lead the way to treatment?DNA microarray analysis of hippocampal gene expression measured twelve hours after hypoxia-ischemia in the mouse.Brain gene expression correlates with changes in behavior in the R6/1 mouse model of Huntington's disease.Sp1 regulates human huntingtin gene expression.Mutant Huntingtin reduces HSP70 expression through the sequestration of NF-Y transcription factor.Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3.Context-dependent dysregulation of transcription by mutant huntingtin.Mutant huntingtin fragment selectively suppresses Brn-2 POU domain transcription factor to mediate hypothalamic cell dysfunction CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model.Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis.cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues.Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease.Wild-type huntingtin protects neurons from excitotoxicity.

P2860

Q24554218-FA571CC2-6293-41FE-9252-157CC015B440 Q26853025-E65D132B-0ECD-4C09-AE91-BA4C72D209FB Q27341821-47EDB7D7-A1C4-458A-AEA3-5268562D53C5 Q30476999-87F6C211-EE28-4119-8050-3A796994747A Q30480364-7E9F2BFB-F872-4FE9-B919-1ABCC23075E1 Q31002507-DD85E0D0-6A03-4524-A7BE-9BC3956ECEF3 Q33755822-B47BC3FE-7E41-4EEA-8DF9-CC7F5F0151EF Q33778522-760B58C5-F645-482F-AF71-3523748C25DF Q33900572-BA404A46-C396-40C6-A46B-1F9C2CF23E90 Q34531481-FAA27F50-238A-463D-B326-17B2525B9074 Q34627066-A3F0995D-CFFD-4AD5-A552-C560BDEAA28A Q34699467-D7266DBB-3C3E-4077-B9BF-EEC7BD31BBC7 Q35024695-9447C8A3-8CE7-4CFB-9B9D-3A60C2C88048 Q35049600-A44C4405-251A-4BDF-8DF8-C493B5FDD4F0 Q35752429-AAAB8CA3-186A-4057-8F4C-ED2078445837 Q35918115-8246B1A2-88D2-468E-AB0F-51A465723931 Q36016647-DD3AA867-1524-4D95-9E8A-A06328293247 Q36016932-52E11DCC-D124-4D39-BAA1-E2352E28523C Q36050548-18D579C8-8D8D-48A0-9475-2F2412E150E5 Q36219680-9A1550AE-B98E-476A-B1FD-A916B3FB80BB Q36525157-C1B5DDC6-F59E-4F69-A6F7-00F42386E679 Q36752799-FF92E9C3-A0D5-4BE9-821E-1C6B320BD5EE Q36767264-AC1989DD-C536-4BF5-9B26-557289154EEB Q37113861-183E0522-1377-4AE7-92CE-639B6980574F Q37154448-100583C5-72C1-475A-92A2-449D96A6AB98 Q37776087-843681B8-F2E4-4663-9199-43F066B46335 Q37840353-85200DD0-D0EA-4007-AF0E-D909ECF36267 Q38349629-05F09878-3DBB-4B91-8A53-C1A1604174DA Q38515686-D7ED8E52-BFFA-4C95-9482-E9F7E698EED1 Q39383676-E66EF530-A6DD-475D-8218-3C69EDA9A5C7 Q40010916-5A3F4C20-87DF-4C20-8102-9D46C47841F1 Q40135127-EADB9E33-10D1-4AD4-BE56-81DA27B17D74 Q40225463-73C4BC85-7CC7-40D5-A4E7-EDCD05C98CE3 Q40392188-5E0B01CC-C604-4633-9CBD-736A2AE07543 Q40437569-B7060452-4CE4-443A-BE54-C363DB57A615 Q42512972-56AE2B77-3F31-4245-851B-C3DF58324DF5 Q44662096-921CDC66-F6A2-420D-BF82-B64BD69B2FBE Q45250028-A5B553AF-26B1-46A1-81B4-59801E796B4D Q45299732-ACC20529-C176-4DCF-B093-05E77D5217F9 Q45299841-53210554-1F41-4039-8ED2-361BF451CC84

P2860

Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.

http://www.wikidata.org/entity/Q38363783

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

Increased huntingtin protein l ...... odels of Huntington's disease.

@en

type

label

Increased huntingtin protein l ...... odels of Huntington's disease.

@en

prefLabel

Increased huntingtin protein l ...... odels of Huntington's disease.

@en

P1433

Q38363783-2F014823-57DA-496A-905D-167A2231C8F7

P1476

Q38363783-3B6A8C87-05D2-4219-B816-A9E7224D3BF4

P2093

Q38363783-39B6F9E0-11E5-43AB-9C0C-8C9812298EF7

Q38363783-405E20B9-A9D3-405D-A7E0-7823B74CDA72

Q38363783-40DE8627-678F-47BB-86EB-D3F24D6094DE

Q38363783-4CDD25F1-7572-4567-B294-F9B82E3FF601

Q38363783-5631C8D6-42ED-4FAC-B16E-99144441944D

Q38363783-56BB4660-C794-41C9-9511-07CC38A87431

Q38363783-601254AD-2864-45DA-AD58-7D8FF8545F81

Q38363783-B57810C3-D7BD-4457-90F3-7121FBC95C3F

Q38363783-C7D3BC7A-7409-443F-A474-53B38F2FE916

Q38363783-EB37C368-AE33-4D45-B50E-EAFC8146002D

P304

Q38363783-6F32F0E6-0773-46FC-ADB0-AEC67A3C31C1

P31

Q38363783-ACD39097-AC19-4DDA-A9B5-4F6196221AC6

P356

Q38363783-1B0A2814-7DCC-47C4-BACC-507C880CC06F

P433

Q38363783-955DB3B7-5E15-4A51-9F92-2A073959C523

P478

Q38363783-F7F1FFEA-3F63-4478-831D-6C1BA4B9D889

P50

Q38363783-1F6C97DA-0649-4BC4-A19A-89B2B6AD07E3

Q38363783-58A3E20B-962C-4024-BCEE-ACADB22CD905

Q38363783-6B6B7300-CDE8-4BFF-8886-A43E4CAA3727

Q38363783-E9C5F591-7044-4C54-B370-3F3D38BF3C3F

P577

Q38363783-2DF26DB8-7D3A-4842-B228-213FC89A5D0E

P5875

Q38363783-B5A3E53D-E2A1-440A-BBFB-726BBA9E81DB

P698

Q38363783-C298B8E3-E0B4-4FEC-876C-B1B942CFB94F

P921

Q38363783-25565207-4D8D-436C-8569-64A439232511

P356

P1433

Human Molecular Genetics

P1476

Increased huntingtin protein l ...... odels of Huntington's disease.

@en

P2093

Andrew Strand

http://www.w3.org/2001/XMLSchema#string

Anne B Young

http://www.w3.org/2001/XMLSchema#string

Edmond Y W Chan

http://www.w3.org/2001/XMLSchema#string

James M Olson

http://www.w3.org/2001/XMLSchema#string

Jang-Ho J Cha

http://www.w3.org/2001/XMLSchema#string

Kathryn O Chase

http://www.w3.org/2001/XMLSchema#string

Marian DiFiglia

http://www.w3.org/2001/XMLSchema#string

Molly M DeJohn

http://www.w3.org/2001/XMLSchema#string

Neil Aronin

http://www.w3.org/2001/XMLSchema#string

Sarah A Hanson

http://www.w3.org/2001/XMLSchema#string

P304

1939-1951

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/HMG/11.17.1939

http://www.w3.org/2001/XMLSchema#string

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Charles Kooperberg

Ruth Luthi-Carter

Michael R. Hayden

Blair R Leavitt

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11220452

http://www.w3.org/2001/XMLSchema#string

P698

12165556

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease